Work

Bronchiolitis Obliterans after Combination Immunotherapy with Pembrolizumab and Ipilimumab

Year: 2018

Type: article

Abstract: Checkpoint inhibitor therapies are members of a new, groundbreaking class of drugs that reinvigorate the immune system to directly attack tumors. A rare side effect of checkpoint inhibitor therapy is pneumonitis, which typically presents as an interstitial lung disease. In this case report, we present a patient in whom combination therapy with the PD-1 inhibitor pembrolizumab and the CTLA-4 inhibitor ipilimumab induced severe airflow obstruction. This is the first report that shows that checkpoint inhibitors may induce airflow limitation.

Source: Journal of Immunotherapy and Precision Oncology

DOI: 10.4103/jipo.jipo_8_18

Authors: Amulya Balagani, Muhammad H Arain, Ajay Sheshadri

Institution: The University of Texas MD Anderson Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,400